VBI's unique investment and incubation model started out of necessity in 2014. Our roots are in drug discovery services, where we operate world-leading and proprietary drug discovery platforms. While serving big pharma customers from around the globe, we came to realize the huge demand from many entrepreneurs who have great ideas but cannot receive funding to advance their plan due to lack of data. We saw the value in many of these innovative ideas and provided our CRO drug discovery services, operational support, and monetary backing to help these creative scientists embark on the "0 to 1" transformation. This spark launched our "equity for service (EFS)" investment and incubation model.
VBI is based in Shanghai, with an office in Boston and personnel in California. As of early 2019, VBI has invested in over 30 companies out of the hundreds of proposals submitted for review and we plan to invest at a rapid pace in the years to come. The majority of our current portfolio companies are US based, but we are open to proposals globally and are excited to see new ideas that fit our investment strategy.
If you would like to learn more about us, please visit: www.vivabioinnovator.com
Or send an email to [email protected]
If you would like to learn more about our parent company, Viva Biotech, please visit: www.vivabiotech.com
Overview
Mentions in press and media 6
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Feb 10, 2022 | New US Laboratory and funding for HAYA Therapeutics | |
| May 20, 2021 | HAYA Therapeutics closes CHF 18 million seed round | |
| May 20, 2021 | HAYA Therapeutics closes CHF 18 million seed round | Along side Broadview Ventures, HAYA Therapeutics’ seed round attracted additional investors including Apollo Health Ventures, BERNINA BioInvest, 4See Ventures, Schroder Adveq and Viva BioInnovator. The startup will use the funds from the fi... |
| Mar 10, 2021 | Viva Biotech Successfully Held 2021 Partnership Summit -- Novel Drug 2021, the Persistence and Transformation of Start-up Founders | SHANGHAI, March 10, 2021 /PRNewswire/ -- March 2nd-6th, 2021, Viva Biotech successfully hosted the 2021 Partnership Summit. Over 300 attendees joined the Summit, including representatives from global investment institutions, R&D heads f... |
| Dec 3, 2019 | Bright Angel Therapeutics Announces New Funding to Advance Therapies for Invasive Fungal Infections | TORONTO – Bright Angel Therapeutics, a biotechnology company focused on developing novel antifungal drugs, today announced an extension to their seed financing round, adding funding that will enable continued advancement of their lead progr... |
Reviews 0
FAQ about Viva BioInnovator
When was Viva BioInnovator founded?
Viva BioInnovator was founded in 2014.
What has the press written about Viva BioInnovator?
Parsers VC has collected 6 articles mentioning Viva BioInnovator, among them “New US Laboratory and funding for HAYA Therapeutics” (Feb 10, 2022) and “HAYA Therapeutics closes CHF 18 million seed round” (May 20, 2021).
Is Viva BioInnovator still active?
Yes, Viva BioInnovator is active; its latest activity on Parsers VC dates from Jun 23, 2022.